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ABSTRACT Health care facility-onset Clostridium difficile infections (HO-CDI) are an
important national problem, causing increased morbidity and mortality. HO-CDI is an
important metric for the Center for Medicare and Medicaid Service’s (CMS) perfor-
mance measures. Hospitals that fall into the worst-performing quartile in preventing
hospital-acquired infections, including HO-CDI, may lose millions of dollars in reim-
bursement. Under pressure to reduce CDI and without a clear optimal method for C.
difficile detection, health care facilities are questioning how best to use highly sensi-
tive nucleic acid amplification tests (NAATs) to aid in the diagnosis of CDI. Our insti-
tution has used a two-step glutamate dehydrogenase (GDH)/toxin immunochro-
matographic assay/NAAT algorithm since 2009. In 2016, our institution set an
organizational goal to reduce our CDI rates by 10% by July 2017. We achieved a sta-
tistically significant reduction of 42.7% in our HO-CDI rate by forming a multidisci-
plinary group to implement and monitor eight key categories of infection preven-
tion interventions over a period of 13 months. Notably, we achieved this reduction
without modifying our laboratory algorithm. Significant reductions in CDI rates can
be achieved without altering sensitive laboratory testing methods.
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Clostridium difficile infections (CDI) result in a substantial burden of morbidity andmortality throughout the United States (1, 2). In 2011, Clostridium difficile was
estimated to cause nearly half a million infections and 29,000 deaths in the United
States, with older adults being especially vulnerable (2, 3). C. difficile is now the most
common pathogen associated with infections in health care facilities (4). Complications
related to CDI include disease recurrence, hospital readmissions, colectomies, death,
and discharge to long-term-care facilities rather than to home (1). CDI are also associ-
ated with rising costs to acute-care facilities, with estimates upwards of $4 billion in
2008 (5).
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There is a continuing debate in the clinical microbiology community concerning the 
optimal approach for the laboratory diagnosis of CDI (6). In the United States, the most 
widely used approach is to test a stool specimen, which takes the form of the cup (i.e., 
diarrheal stool), with an FDA-approved nucleic acid amplification test (NAAT), which 
detects genes involved in C. difficile toxin synthesis (6). An alternative approach is a 
two-step algorithm where an immunochromatographic screening test is done which 
detects a cell wall antigen of C. difficile, glutamate dehydrogenase (GDH), and C. difficile 
toxins. If the test is positive for both analytes, the patient’s laboratory diagnosis is CDI; 
if negative for both, the patient is negative for CDI. In patients who are GDH positive/
toxin negative (approximately 10 to 15%), an NAAT is performed, and the determina-
tion of CDI laboratory diagnosis is based on the NAAT result (7). A third approach is to 
use NAAT or GDH testing as the initial screen, and for those that are positive by that 
screen, use toxin enzyme immunoassay (EIA) as the confirmatory test; those who are 
toxin positive by the EIA are considered to be positive for CDI, while those who are 
negative are considered carriers of C. difficile (8). Outcome studies suggest this ap-
proach is the most specific for CDI diagnosis, although whether it is the most sensitive 
is debated (6). The most recently published clinical practice guidelines from the 
Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology 
of America (SHEA) recommend testing stools from patients who have unexplained 
new-onset diarrhea, defined as 3 stools in 24 hours, and who have not received 
laxatives in the prior 48 hours with the use of a NAAT alone or a stool toxin test as part 
of a multiple-step testing algorithm (i.e., GDH plus toxin, GDH plus toxin mediated by 
NAAT, or NAAT plus toxin) (9).
A major driver of this debate is the Center for Medicare and Medicaid Service’s (CMS) 
hospital-acquired condition (HAC) reduction program (10). As a result of this program, 
institutions have focused intense efforts on reducing HACs, which include infections 
that occur in hospitals and were not present on admission. In October 2016, CMS began 
counting health care facility-onset (HO) CDI that were laboratory identified (LabID) as 
HACs. CDI LabID is defined by the National Healthcare Safety Network (NHSN) as any 
positive laboratory test result for C. difficile toxin A and/or B, or any detection of 
toxin-producing C. difficile organisms by culture or other laboratory means on an 
unformed stool specimen (11). For the purposes of the CMS HAC reduction program, 
HO-CDI LabID is defined as a positive laboratory test specimen collected greater than 
3 days after admission to the facility. Hospitals that rank in the worst-performing quartile 
in preventing HACs, including HO-CDI LabID, experienced a 1% payment reduction begin-
ning in fiscal year 2017 (FY17). For large medical centers, this payment reduction may put 
millions of dollars in reimbursement at risk. As a result, there has been an increased 
emphasis on reducing CDI rates within health care institutions (6, 12).
Since 2008, an increasing number of institutions have turned from enzyme 
immunoassays (EIA) to NAAT to perform C. difficile testing, due to the high 
sensitivity and relatively short turnaround time of NAAT. Despite risk adjustment 
from the NHSN on testing methodology (13), the resulting increase in C. difficile-
positive results with NAAT may amplify the pressure on institutions to improve their 
infection rates (14). At our institution, the University of North Carolina Medical 
Center (UNCMC), a 933-bed academic hospital, we have used a two-step GDH/toxin 
immunochromatographic assay (C. diff Quik Chek Complete; TechLab, Blacksburg, 
VA) and NAAT (GeneXpert C. difficile; Cepheid, Sunnyvale, CA) algorithm since 2009 
(7). Our HO-CDI LabID rate for FY16 was 11.0 infections per 10,000 patient days. CDI 
was consistently the most common cause of health care-associated infections in 
FY16 at UNCMC. Starting in April 2016, we sought to reduce our HO-CDI LabID rate 
by 10% by July 2017. We began by forming a multidisciplinary team to design and 
implement evidence-based interventions to prevent patient harm from C. difficile. In  
this paper, we describe the bundle of infection prevention approaches our team 
implemented to reduce CDI rates at UNCMC.
MATERIALS AND METHODS
Our multidisciplinary group met on a monthly basis to organize and coordinate our efforts. This 
group included representatives from Hospital Epidemiology, Performance Improvement and Patient 
Safety (PIPS), Clinical Microbiology, Antimicrobial Stewardship, Pharmacy, Infectious Disease, Environ-
mental Services, Nursing, Patient Equipment, and Hospital Administration. The multidisciplinary group 
implemented multiple interventions and monitored the progress of each intervention with process 
measures. The interventions fell into eight discrete categories, as follows: diagnostic stewardship, 
electronic tools to enhance diagnostic stewardship, education, enhanced isolation precautions, hand 
hygiene, environmental cleaning and disinfection, antimicrobial stewardship, and pharmaceutical inter-
ventions (Table 1). The majority of the interventions were novel for our facility, but some (e.g., hand 
hygiene) focused on sustaining existing interventions that were already in place within our facility. The 
first new intervention began in March 2016, with implementation of the final intervention in May 2017 
(Fig. 1).
Diagnostic stewardship. With the advent of highly sensitive NAATs, testing standards are necessary 
to ensure that the patient’s clinical status warrants testing for CDI (14). Prior to convening the 
multidisciplinary group, the microbiology laboratory enforced C. difficile testing only for unformed, liquid 
stool and restricted testing for children less than 12 months of age without approval from a pediatric 
infectious disease physician. Starting in March 2016, the microbiology laboratory began enforcing other 
testing standards. Tests ordered on samples from patients with a positive C. difficile test in the previous 
14 days were canceled, as this would not alter clinical management. Bolstered by evidence that repeat 
testing to detect CDI holds little value (9, 15), the microbiology laboratory also canceled tests ordered on 
patients with a negative C. difficile result in the previous 7 days. However, testing was considered on a 
case-by-case basis if the patient experienced new unexplained fever, abdominal pain, and leukocytosis 
in the 7 days after the first negative test.
Our laboratory standards discouraged testing of patients who received laxatives and/or stool 
softeners in the previous 48 h to reduce the risk of testing patients without clinically significant diarrhea, 
based on best practices documented in the literature (12, 16). Our standards also discouraged testing 
patients who had been continuously symptomatic since their last positive test, as well as asymptomatic 
patients who had completed antibiotic therapy (avoiding a “test of cure”) (9). “Clinically significant” 
diarrhea was defined as “3 liquid stools in a 24-hour period, by history or observation” (9). The 
microbiology laboratory was able to enforce certain standards (i.e., no testing within 7 days of a previous 
negative result and no testing within 14 days of a previous positive result) by viewing results in the 
patient’s electronic medical record and canceling orders. However, enforcing other standards (i.e., no 
testing within 48 h of a dose of laxative and/or stool softener, testing only clinically significant diarrhea) 
would have produced an unsustainable workload for the microbiology laboratory. Therefore, it was 
necessary for Hospital Epidemiology to improve diagnostic stewardship by using tools within our 
electronic medical record.
Hospital Epidemiology and PIPS worked to modify our electronic record, Epic (Verona, WI), to create 
automated prompts based on the laboratory testing standards for clinicians ordering C. difficile testing 
(Fig. 2). The prompts were not hard stops; they were meant to remind health care personnel (HCP) of 
testing per hospital policy (e.g., only testing patients with clinically significant diarrhea and not testing 
patients who received laxatives in the previous 48 h). HCP were not prevented from ordering a test if they 
left the questions unanswered or answered them incompletely.
We also developed automated best practice advisories (BPAs) within Epic to inform HCP of appro-
priate testing based on the laboratory testing standards (Fig. 3). The BPAs act as an alert when HCP order 
C. difficile tests on patients with recent C. difficile results and/or documented laxative or stool softener use 
in the last 48 h based on medication administration records. Like the electronic prompts, the BPAs were 
meant to act as educational tools and reminders and were not hard stops, with the intent that the BPAs 
and ordering questions could become mandatory if auditing revealed a lack of improvement in 
diagnostic stewardship. The ordering questions were implemented in the medical record in October 
2016, and the BPAs were implemented in March 2017. Compliance with testing standards was assessed 
by electronic audits of nursing documentation of laxative or stool softener administration in the 48 hours 
prior to testing and loose stools. Compliance with no prior testing within 7 days of a previous negative 
or 14 days of a previous positive was assessed by electronic audits of documented laboratory results in 
the patient’s chart. The audits were performed monthly for all inpatients with C. difficile testing orders.
Education. In April 2016, an update on C. difficile testing per hospital policy was disseminated to 
physician leadership. Registered nurses were empowered to use a standing protocol based on laboratory 
testing standards to place an order for C. difficile testing for symptomatic patients. Education was 
presented at nursing staff meetings in April 2016 and disseminated to nursing leadership. The standing 
protocol was updated with the intent to expedite testing on symptomatic patients when appropriate in 
order to initiate isolation and treatment.
Enhanced isolation precautions. At our facility, patients with known or suspected (i.e., at the time 
of C. difficile testing order) CDI are placed on enteric precautions, an enhanced version of contact 
precautions. Enteric precautions require a private room, gloves when entering the room, a disposable 
gown and gloves for direct patient contact or whenever clothing may contact room surfaces, and hand 
hygiene with soap and water after removing gloves and/or exiting the room. Visitors are also required 
to wear a gown and gloves and perform hand hygiene with soap and water. Starting in April 2016, 
Hospital Epidemiology increased the duration of enteric precautions from cessation of antibiotic therapy 
to 30 days after the cessation of antibiotic therapy, based on evidence of persistent stool, skin, and 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FIG 1 Health care facility-onset C. difficile LabID rates and novel interventions, 2015 to 2017.
this change was implemented and periodically monitored staff and visitor compliance with point 
prevalence surveys.
Since reducing CDI was an organizational goal for our facility, nurses working in the surgery service 
produced a novel intervention directed toward CDI prevention in February 2017. Nurses created a new 
enteric precautions sign that incorporated visual cues to prompt improved compliance with personal 
protective equipment (PPE) in isolation rooms.
Environmental cleaning and disinfection. Environmental cleaning has been shown to be an 
integral part of CDI prevention (18, 19). Enhanced cleaning practices in enteric precautions rooms include 
the use of an EPA-registered cleaner with known sporicidal activity during daily cleans and at patient 
discharge. Since 2012, the environmental services staff also used UV light (UV-C) machines to terminally 
disinfect patient rooms after cleaning following patient discharge (Healthcare Optimum-UV Enlight or 
Tru-D SmartUVC). The thoroughness of cleaning was monitored on a regular basis with the application 
of fluorescent dye on surfaces as a surrogate measure for the removal of organic soil. Frontline staff 
received feedback on the results of the cleaning audits. Environmental services monitored enteric 
precautions rooms for terminal disinfection with UV-C machines at discharge. There was a lack of 
equipment cleaning standardization throughout the hospital, with units utilizing different departments 
to clean pieces of equipment (e.g., vital sign machines and intravenous [i.v.] pumps). Beginning in May 
2016, PIPS led a second multidisciplinary group to create a standardized plan for cleaning both patient 
rooms and pieces of patient equipment throughout the hospital.
Antimicrobial stewardship and pharmacy interventions. As antimicrobial therapy can precipitate 
CDI, reducing the use of unnecessary antibiotics is crucial in preventing CDI (20). Our antimicrobial 
stewardship program, staffed by infectious disease physicians, infectious disease pharmacists, and a 
clinical microbiologist, began providing support through antimicrobial surveillance, prospective audits 
and feedback, and educational activities, including in-services to all pharmacists on CDI and laboratory 
testing standards in July 2016. Prior to that time, more limited surveillance of redundant antimicrobial 
regimens and bloodstream infections started in July 2014. Electronic alerts generated by the TheraDoc 
(Premier, Inc., Charlotte, NC) software module for antimicrobial stewardship included bug-drug mis-
matches, dual anaerobic coverage, dual antistaphylococcal coverage, and positive blood cultures. In 
2016, the antimicrobial stewardship team specifically worked to reduce the use of third- and fourth-
generation cephalosporins and fluoroquinolones, which have been associated with increased rates of CDI 
(21).
Proton pump inhibitors (PPI) are overused in hospitalized patients (22) and have been associated
with an increased risk for CDI (23, 24, 25). Pharmacy representatives on the multidisciplinary team
developed educational guidelines for PPI use at UNCMC. When PPI use was clinically indicated, the
guidelines supported using the lowest dose possible for the shortest duration of time possible and
avoiding dose escalation. The guidelines were presented to UNCMC pharmacists in March 2017 and to
intensive care unit physician and nurse leaders in July 2017.
Hand hygiene. Meticulous hand hygiene remains a bedrock of CDI prevention (26, 27). Since 2014,
UNCMC has measured hand hygiene compliance through “Clean In, Clean Out,” a system of observations
FIG 2 Electronic prompts for C. difficile testing.
FIG 3 Electronic best practice advisories for C. difficile testing.
conducted by frontline personnel with immediate feedback. Prior to implementation of this program, 
hand hygiene rates were static and remained at less than 90%. Since implementation of the observation 
system, compliance rates have consistently been greater than 90%, with at least half of the thousands 
of inpatient observers offering immediate feedback. Our multidisciplinary group made a concerted effort 
to sustain hand hygiene compliance through education and special incentives.
Statistical analysis. A two-tailed Chi-square test was used to compare data for CDI rates before and 
after our bundle of interventions were implemented. A P value of 0.05 was considered statistically 
significant. Statistical analysis was performed using the SAS software (version 9.3; SAS Institute, Cary, NC, 
USA).
RESULTS
In FY17, our HO-CDI LabID rate decreased to 6.30 infections per 10,000 patient days 
(95% confidence interval [CI] 5.30 to 7.40), representing a statistically significant (P  
0.05) decrease of 42.7% from the FY16 rate of 11.0 infections per 10,000 patient days 
(95% CI, 9.60 to 12.40) (Fig. 3). HO-CDI LabID rates from prior years also demonstrated 
a reduction in infection rates; in FY13, the rate was 7.60; in FY14, it was 9.00; and in 
FY15, it was 9.70. Our FY17 rate then represents a decrease of 17 to 35% from previous 
years. These decreases occurred during a time period when community-onset CDI rates 
actually increased, ranging from 4.7 infections in FY13 to 6.9 infections in FY17. 
Importantly, our decrease in HO-CDI has been sustained over time, with HO-CDI LabID 
rates of 4.60 and 5.30 in the first and second quarters of FY18, respectively.
A previous study using linear regression to estimate the cost of CDI found that 
acute-care-facility costs were at least $3,006 per case (includes community and hospital 
onset in 2008 dollars) (5). Using this estimate, our 100 fewer infections in FY17 
potentially saved our facility approximately $300,600 in costs associated with CDI. 
Without further, more extensive analysis, this cost savings could not be considered an 
outright financial gain, but it is important to note that none of the interventions 
implemented in this bundle required an additional financial investment. All interven-
tions were undertaken using existing resources and staff.
Provider compliance with testing per hospital policy was also significantly improved 
in the same time frame. Provider compliance with testing was measured by the 
following data that could be directly abstracted from the patient’s electronic medical 
record: no previous positive test in the last 14 days, no previous negative test in the last 
7 days, no laxatives or stool softeners administered in the 48 hours prior to testing, and 
loose stools documented. Eight months after the ordering prompts were instituted and 
3 months after the BPAs, overall compliance with testing (i.e., all four measured 
components met hospital policy for each ordered C. difficile test) had improved from 
65.6% in July 2016 to 77.6% in June 2017 (P  0.01). In the same time period, 
compliance with each individual testing component improved as well. Electronic audits 
showed that loose stool documentation increased from 85.6% to 87.1%; no laxative 
administration within 48 hours prior to testing increased from 85.6% to 92.4%; no 
testing within 7 days of a previous negative increased from 90.5% to 97.6%; and no 
testing 14 days of a previous positive increased from 90.5% to 100% (Table 1). The 
overall number of C. difficile tests also decreased during the intervention period. In 
2016, the average number of C. difficile tests ordered per month was 309. In 2017, the 
average number of tests ordered per month was 217.
Retrospective house-wide audits of electronic documentation in Epic showed in-
creased compliance with the use of UV-C at discharge cleaning for enteric precautions 
rooms in a comparison of the month of August 2016 with October 2017 (Table 1). 
Environmental service audits of cleaning compliance with fluorescent dye on inpatient 
room touchpoints showed high monthly compliance that was not significantly changed 
from FY16 to FY17.
Point prevalence surveys performed by Hospital Epidemiology in June 2016 showed 
high HCP compliance (93%) with PPE in enteric precautions rooms. In December 2017, 
repeat point prevalence surveys showed decreased HCP compliance with PPE (80%)
(Table 1).
Our hand hygiene compliance remained consistently high in the 11-month inter-
vention implementation period. Our goal was to maintain  90% hand hygiene com-
pliance in  90% of participating areas, with immediate feedback on hand hygiene 
performance offered in 75% of observations. In FY17, all inpatient units consistently 
sustained more than 90% hand hygiene compliance (Table 1). Our monthly average 
feedback percentage on hand hygiene compliance was 54% across inpatient settings.
Our antimicrobial stewardship goal was to reduce the days of therapy per 1,000 
patient days of third- and fourth-generation cephalosporins and fluoroquinolones 
associated with CDI. From FY16 to FY17, cefepime, ceftazidime, and levofloxacin use all 
decreased significantly (Table 1). Clindamycin days of therapy were also reduced. 
However, there was a statistically significant increase in ceftriaxone use in the same time 
period.
DISCUSSION
From FY16 to FY17, we were able to significantly reduce our HO-CDI LabID rate and 
sustain the reduction without altering our laboratory testing methodology. While other 
published approaches to CDI reduction have included multidisciplinary teams (28), 
automated electronic health record protocols (29), diagnostic stewardship (30), routine 
cleaning with sporicidal disinfectants (31) and UV light disinfection (32), and antimi-
crobial stewardship (21), our approach is the first published one, to our knowledge, to 
include multiple process measures demonstrating a reduction in CDI with evidence-
based practices.
There was also an overall decrease in C. difficile testing from FY16 to FY17. This may, 
in part, indicate improved diagnostic stewardship on the part of ordering providers. 
Lending credence to this theory, provider ordering compliance to hospital policy 
significantly improved after the institution of electronic ordering prompts and BPAs.
Our multidisciplinary CDI prevention group was a key strength of our approach. The 
coordinated use of multiple disciplines to address CDI is recommended as a method to 
control CDI, due to the inherent complexity of preventing this type of infection (24). Our 
facility’s leadership supported the creation of this working group and the imple-
mentation of our intervention bundle. Consensus from all the stakeholders in the 
multidisciplinary group ensured that our interventions were well-thought through and 
evidence based. In addition, leveraging existing resources in the hospital for these 
efforts was cost-effective and efficient, considering that the mean cost of CDI is $3,006 
per case. While an estimated savings of greater than $300,000 may be an overestimate, 
as it does not take into account other factors, it provides evidence that reduced 
infections can result in significant cost savings to facilities beyond simply reducing CMS 
penalties. No additional staff members were hired to implement any intervention, and 
we leveraged existing resources (e.g., our current medical record and our current UV-C 
machines) to achieve our goal. Our two-step testing algorithm had been in place since 
2009 and represented no additional cost.
Importantly, laboratory testing methods were not altered during this study, so 
changes in CDI rates cannot be attributed to using a different testing strategy in which 
NAAT or GDH screening is first done and then followed by a confirmatory test with a 
relatively less-sensitive testing method.
Because multiple interventions were implemented during the same time period and 
because some efforts were focused on sustaining existing interventions (e.g., hand 
hygiene), it is difficult, if not impossible, to assign the reduction in CDI to any single 
intervention.
While there has been no evidence of worsened clinical outcomes due to enhanced 
testing standards, we did not specifically conduct surveillance to assess for potential 
missed diagnoses, nor did we have a baseline of CDI-related adverse outcomes. It is 
possible that there were patients who might have had delays in being diagnosed with 
CDI because they had received laxatives in the 48 h prior to testing or had a negative C. 
difficile assay result in the 7 days prior to testing. However, we felt reasonably confident 
that adverse patient outcomes would have been reported if they had truly occurred 
because our facility has a robust patient safety reporting system, and prac-
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ticing adult and pediatric infectious disease physicians and infectious disease pharma-
cists were part of our multidisciplinary group.
Alert fatigue was a concern when we implemented our electronic ordering prompts and 
BPAs. It is possible that rather than acknowledging the messages in the electronic ordering 
prompts and BPAs, HCP became inured to the alerts and simply stopped paying attention 
to them. However, our overall success in reducing our HO-CDI LabID rates and increased 
compliance with testing per hospital policy even without making these alerts and BPAs 
hard stops lead us to believe that the prompts and BPAs succeeded in reaching a significant 
number of ordering clinicians. Because neither the prompts nor the BPAs contained hard 
stops, provider compliance with testing per policy must be monitored closely to ensure 
that the intervention continues to be sustained.
There were mixed results from our other process measures. Our institution had 
success in overall reductions in the use of antibiotics that commonly precipitate CDI, in 
sustaining hand hygiene compliance rates, and in improving the use of UV-C at 
terminal cleaning for enteric precautions rooms. However, HCP compliance with ap-
propriate gowning and gloving in enteric precautions rooms actually decreased over 
the same time period. The exact reasons behind this are unclear. It may be that 
compliance with enteric precautions is more susceptible to individual error and that an 
annual point prevalence survey is not frequent enough to remind HCP about the 
importance of following enteric precautions, while more frequent audits and in-person 
reminders from other HCP helped sustain or improve the other process measures. Also, 
as our point prevalence survey occurred on a single day, it may not accurately represent 
PPE compliance in our facility.
There was a slight decrease in CDI LabID rates from October 2015 to April 2016, prior to 
organization of the multidisciplinary group and implementation of the majority of the 
interventions (Fig. 1). However, the most significant decline in the number of LabID CDI 
events occurred from April 2016 through March 2017, the time period when the majority 
of our interventions were implemented. While the initial decline in CDI cases may be due 
to natural fluctuation or other factors, such as a consistently high rate of hand hygiene, it 
is unlikely that our most significant rate reductions and continued sustainment were due 
to chance or other factors. One limitation of this bundle of interventions is the potential 
need for continued monitoring of rates. With the exception of the testing prompts and the 
BPAs, our interventions are not automated and require effort to sustain them through 
auditing, education, and communication to frontline HCP.
In conclusion, through use of a multidisciplinary group and implementation and 
monitoring of multiple interventions, our facility was able to effectively reduce our 
HO-CDI LabID rate while still using a highly sensitive laboratory testing method. We 
demonstrated that engaging a wide group of stakeholders and implementing a variety 
of evidence-based interventions was an effective way to significantly lower our HO-CDI 
LabID rates without altering our laboratory algorithm.
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